GT199800200AA - Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200). - Google Patents

Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200).

Info

Publication number
GT199800200AA
GT199800200AA GT199800200AK GT199800200K GT199800200AA GT 199800200A A GT199800200A A GT 199800200AA GT 199800200A K GT199800200A K GT 199800200AK GT 199800200 K GT199800200 K GT 199800200K GT 199800200A A GT199800200A A GT 199800200AA
Authority
GT
Guatemala
Prior art keywords
azapolyclic
aryl
compounds
derived
compounds condensed
Prior art date
Application number
GT199800200AK
Other languages
English (en)
Spanish (es)
Inventor
Jothan Wadsworth Coe
Paige Roanne Palmer Brooks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT199800200A(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT199800200AA publication Critical patent/GT199800200AA/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GT199800200AK 1997-12-31 1998-12-15 Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200). GT199800200AA (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31

Publications (1)

Publication Number Publication Date
GT199800200AA true GT199800200AA (es) 2000-06-07

Family

ID=22094096

Family Applications (2)

Application Number Title Priority Date Filing Date
GT199800200AK GT199800200AA (es) 1997-12-31 1998-12-15 Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200).
GT199800200A GT199800200A (es) 1997-12-31 1998-12-15 Compuestos azapoliciclicos condensados con arilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GT199800200A GT199800200A (es) 1997-12-31 1998-12-15 Compuestos azapoliciclicos condensados con arilo.

Country Status (51)

Country Link
US (6) US6410550B1 (enExample)
EP (2) EP1044189B2 (enExample)
JP (1) JP3550359B2 (enExample)
KR (1) KR100408138B1 (enExample)
CN (2) CN1324013C (enExample)
AP (1) AP1170A (enExample)
AR (1) AR017967A1 (enExample)
AT (1) ATE386024T1 (enExample)
AU (1) AU753389C (enExample)
BG (1) BG65058B1 (enExample)
BR (2) BR9814592B1 (enExample)
CA (1) CA2316921C (enExample)
CO (1) CO4810373A1 (enExample)
CY (2) CY1107391T1 (enExample)
CZ (1) CZ301925B6 (enExample)
DE (2) DE122008000038I1 (enExample)
DK (1) DK1044189T4 (enExample)
DZ (1) DZ2697A1 (enExample)
EA (1) EA003190B1 (enExample)
EG (1) EG23816A (enExample)
ES (1) ES2301210T5 (enExample)
FR (1) FR08C0039I2 (enExample)
GT (2) GT199800200AA (enExample)
HN (1) HN1998000177A (enExample)
HR (2) HRP20000445B1 (enExample)
HU (2) HU230297B1 (enExample)
IL (2) IL136727A0 (enExample)
IS (1) IS5514A (enExample)
LU (1) LU91442I2 (enExample)
MA (1) MA26589A1 (enExample)
ME (1) ME00459B (enExample)
MY (1) MY118163A (enExample)
NL (1) NL300355I2 (enExample)
NO (2) NO319115B1 (enExample)
NZ (1) NZ504482A (enExample)
OA (1) OA11428A (enExample)
PA (1) PA8463901A1 (enExample)
PE (1) PE20000053A1 (enExample)
PL (1) PL209404B1 (enExample)
PT (1) PT1044189E (enExample)
RS (1) RS50069B (enExample)
SA (1) SA99191123B1 (enExample)
SG (1) SG102686A1 (enExample)
SI (1) SI1044189T2 (enExample)
SK (1) SK286886B6 (enExample)
TN (1) TNSN98237A1 (enExample)
TR (1) TR200001840T2 (enExample)
TW (1) TW513412B (enExample)
UA (1) UA66825C2 (enExample)
WO (1) WO1999035131A1 (enExample)
ZA (1) ZA9811911B (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
ATE386024T1 (de) * 1997-12-31 2008-03-15 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
AU781084B2 (en) 1999-07-28 2005-05-05 Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
CZ20032814A3 (cs) * 2001-04-20 2004-08-18 Pfizeráproductsáinc Způsob přípravy �Ź@@substituovaných indenů a aryl@kondezovaných azapolycyklických sloučenin
CA2446988A1 (en) * 2001-05-14 2002-11-21 Pfizer Products Inc. The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
ATE405574T1 (de) 2001-11-30 2008-09-15 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
DE60218885T2 (de) * 2001-11-30 2008-01-17 Pfizer Products Inc., Groton Orale pharmazeutische Arzneiformen bzw. Dosierungsformen von 5,8,14-Triazatetra-cyclo-(10.3.1.0 (2,11).0(4,9)-hexadeca-2(11),3,5,7,9-pentaen mit kontrollierter Freisetzung
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
AU2003215272B2 (en) * 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7605150B2 (en) * 2002-05-14 2009-10-20 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
ES2307974T3 (es) * 2002-11-20 2008-12-01 Pfizer Products Inc. Procedimiento de preparacion de acido indan-1,2-dicarboxilico.
ATE554392T1 (de) 2002-11-20 2012-05-15 Univ Leland Stanford Junior Diagnoseverfahren für sprue/zöliakie
JP2006507342A (ja) * 2002-11-25 2006-03-02 ファイザー・プロダクツ・インク １，３−置換インデンを製造するための改良方法
AU2004203983A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
DK1638971T3 (da) * 2003-06-04 2008-10-27 Pfizer Prod Inc Fremstilling af substitueret Quinoxaliner fra dianilinen med 2,3-dihydroxy-1,4-dioxan
ES2331245T3 (es) * 2003-07-21 2009-12-28 Pfizer Products Inc. Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
ES2313625T3 (es) * 2005-02-24 2009-03-01 Pfizer Products Incorporated Preparacion de una quinoxalina sustituida de alta pureza.
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
CA2644448A1 (en) * 2006-03-27 2007-10-04 Pfizer Products Inc. Varenicline standards and impurity controls
AU2007242526A1 (en) * 2006-04-24 2007-11-01 Pfizer Products Inc. Asymmetric membranes for drug delivery devices
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
MX2009005043A (es) * 2006-11-09 2009-05-25 Pfizer Prod Inc Polimorfos de intermedios nicotinicos.
EP2136833B1 (en) * 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
EP2260037A2 (en) * 2008-02-15 2010-12-15 Medichem, S.A. A polymorphic form of a pyrazino [2,3-h] [3] benzazepine derivative
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
EP2271344A4 (en) * 2008-03-31 2011-04-27 Univ South Florida METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE
EP2268639A2 (en) * 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2204369A1 (en) 2008-12-22 2010-07-07 Medichem, S.A. Process for preparing varenicline and intermediates for use therein
AU2010214101A1 (en) 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
US20120093887A1 (en) 2009-06-10 2012-04-19 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
US8178537B2 (en) 2009-06-22 2012-05-15 Teva Pharmaceutical Industries Ltd. Solid state forms of varenicline salts and processes for preparation thereof
JP2013504580A (ja) * 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法
CA2791460A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
CN103619354A (zh) 2011-06-30 2014-03-05 东丽株式会社 止痒剂
ITMI20111413A1 (it) 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
US11266658B2 (en) 2017-03-03 2022-03-08 Ctc Bio, Inc. Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
US12569498B2 (en) 2019-11-06 2026-03-10 Children's National Medical Center Methods and compositions for the prevention and treatment of ischemia reperfusion injury and infection
EP4142734B1 (en) 2020-04-28 2025-08-20 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Varenicline prodrugs
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
US20250134904A1 (en) 2021-12-23 2025-05-01 Medichem, S.A. Solid pharmaceutical formulations of varenicline
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
JP2025520426A (ja) 2022-06-14 2025-07-03 アミグダラ ニューロサイエンシーズ， インコーポレイテッド Ａｌｄｈ－２阻害化合物及び使用方法
EP4540228A1 (en) 2022-06-14 2025-04-23 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en) 2022-11-04 2024-05-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines
IT202300003888A1 (it) 2023-03-03 2024-09-03 Dipharma Francis Srl Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Varenicline formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
EP0853621A1 (en) † 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
ATE386024T1 (de) * 1997-12-31 2008-03-15 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
KR100420423B1 (ko) * 1998-04-29 2004-03-04 화이자 프로덕츠 인코포레이티드 아릴 축합된 아자 다환식 화합물
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
CA2446988A1 (en) * 2001-05-14 2002-11-21 Pfizer Products Inc. The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
DE60218885T2 (de) * 2001-11-30 2008-01-17 Pfizer Products Inc., Groton Orale pharmazeutische Arzneiformen bzw. Dosierungsformen von 5,8,14-Triazatetra-cyclo-(10.3.1.0 (2,11).0(4,9)-hexadeca-2(11),3,5,7,9-pentaen mit kontrollierter Freisetzung
ATE405574T1 (de) * 2001-11-30 2008-09-15 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.

Also Published As

Publication number Publication date
BR9814592B1 (pt) 2010-06-01
US20020111350A1 (en) 2002-08-15
PT1044189E (pt) 2008-04-22
TW513412B (en) 2002-12-11
ZA9811911B (en) 2000-06-29
HRP20000445B1 (hr) 2009-04-30
HUP0100949A3 (en) 2002-12-28
OA11428A (en) 2004-05-03
IS5514A (is) 2000-05-26
BR9814592A (pt) 2000-10-17
NL300355I2 (nl) 2008-11-03
NO319115B1 (no) 2005-06-20
EP1044189B2 (en) 2015-02-25
CN1285821A (zh) 2001-02-28
AU753389C (en) 2007-08-09
CZ301925B6 (cs) 2010-08-04
AP9801422A0 (en) 1998-12-31
EA003190B1 (ru) 2003-02-27
HU230297B1 (hu) 2015-12-28
AU753389B2 (en) 2002-10-17
SK286886B6 (sk) 2009-07-06
CA2316921A1 (en) 1999-07-15
NO2006016I2 (enExample) 2008-10-20
DK1044189T3 (da) 2008-05-13
HK1031878A1 (en) 2001-06-29
LU91442I2 (fr) 2008-07-21
CY2008013I2 (el) 2009-11-04
LU91442I9 (enExample) 2018-12-31
YU40300A (sh) 2003-10-31
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (en) 2008-02-13
MY118163A (en) 2004-09-30
PL209404B1 (pl) 2011-08-31
HUS1600018I1 (hu) 2018-05-02
KR100408138B1 (ko) 2003-12-01
FR08C0039I1 (enExample) 2008-11-14
HRP20050506A2 (en) 2006-03-31
CO4810373A1 (es) 1999-06-30
UA66825C2 (uk) 2004-06-15
JP2002500218A (ja) 2002-01-08
ATE386024T1 (de) 2008-03-15
US6951938B2 (en) 2005-10-04
GT199800200A (es) 2000-06-07
US20020072525A1 (en) 2002-06-13
AU9641698A (en) 1999-07-26
NO20003422L (no) 2000-08-29
AR017967A1 (es) 2001-10-24
US20020132824A1 (en) 2002-09-19
TNSN98237A1 (fr) 2005-03-15
BG104561A (en) 2001-01-31
PA8463901A1 (es) 2000-09-29
SG102686A1 (en) 2004-03-26
MA26589A1 (fr) 2004-12-20
SK9712000A3 (en) 2002-03-05
TR200001840T2 (tr) 2000-12-21
EP1044189A1 (en) 2000-10-18
HN1998000177A (es) 1999-02-09
NL300355I1 (nl) 2008-08-01
US6897310B2 (en) 2005-05-24
US20070275973A1 (en) 2007-11-29
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (en) 1999-07-15
NO20003422D0 (no) 2000-06-30
IL136727A0 (en) 2001-06-14
AP1170A (en) 2003-06-30
BR9816186B1 (pt) 2009-01-13
EG23816A (en) 2007-09-19
DZ2697A1 (fr) 2003-03-29
PL341824A1 (en) 2001-05-07
US20020072524A1 (en) 2002-06-13
CY1107391T1 (el) 2010-07-28
CN1715280A (zh) 2006-01-04
EP1659114A2 (en) 2006-05-24
IL136727A (en) 2006-06-11
NZ504482A (en) 2003-01-31
DK1044189T4 (en) 2015-03-30
KR20010033823A (ko) 2001-04-25
CY2008013I1 (el) 2009-11-04
RS50069B (sr) 2009-01-22
NO2006016I1 (no) 2006-11-27
SI1044189T1 (sl) 2008-06-30
HRP20000445A2 (en) 2001-04-30
HUP0100949A2 (hu) 2001-08-28
DE69839131D1 (de) 2008-03-27
US6410550B1 (en) 2002-06-25
SI1044189T2 (sl) 2015-05-29
FR08C0039I2 (fr) 2009-12-18
ME00459B (me) 2011-10-10
CN1324013C (zh) 2007-07-04
CZ20002438A3 (cs) 2002-11-13
DE122008000038I1 (de) 2008-11-13
US6887884B2 (en) 2005-05-03
BG65058B1 (bg) 2007-01-31
CA2316921C (en) 2004-12-07
EP1659114A3 (en) 2007-01-17
DE69839131T3 (de) 2015-05-07
JP3550359B2 (ja) 2004-08-04
SA99191123B1 (ar) 2006-10-02
DE69839131T2 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
GT199800200A (es) Compuestos azapoliciclicos condensados con arilo.
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
GT199800058A (es) Derivados de nicotinamida.
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
UY27258A1 (es) Derivados de dihidro-benzo b 1, 4 diazepin-2-ona como antagonistas ii mglur2
PT884316E (pt) Quinazolina-4-ona como antagonistas do mapa
ATE368458T1 (de) Chronische bolusgabe von d-threo methylphenidat
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
GT199800205A (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgesicos.
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
AR028705A1 (es) Bis-arilsulfonas
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
DE602004020042D1 (de) er SSRI zur Behandlung von Stimmungs- oder Angststörungen
AR010122A1 (es) Procedimiento de recuperacion de vwf altamente purificado o complejo de factor viii/vwf altamente purificado
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
ATE411283T1 (de) (20s)-1 alpha-hydroxy-2-methylen-19-nor- bishomopregnacalciferol und ihre verwendungen
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
BR0210401A (pt) Composto, composição farmacêutica, uso de um composto e método para o tratamento de um distúrbio ou de uma doença de um corpo de animal vivo, incluindo um humano
BR0112131A (pt) Composições farmacêuticas e métodos para uso
DE69832302D1 (de) Antikonvulsive und zns-aktive bis-fluoralkylamide
GT200100184A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso.
PA8642901A1 (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa i
GT199800147A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
BR0210407A (pt) Composto, composição farmacêutica, uso de um composto e método de tratamento de um distúrbio ou de uma doença de corpo animal vivo, incluindo um humano